Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Neurophysiol Clin ; 54(4): 102984, 2024 May 16.
Article in English | MEDLINE | ID: mdl-38759365

ABSTRACT

Botulinum neurotoxin serotype A (BoNT-A) has several therapeutic indications such as spasticity and dystonia. Although its use is generally considered safe, a systemic diffusion can lead to systemic complications, and a botulism-like syndrome can occur after intramuscular injections. Herein, two adult cases who developed general muscle weakness after a BoNT-A intramuscular injection are reported. Both presented with a progressive decrement on low-frequency (LF) repetitive nerve stimulation (RNS). It is suggested that a progressive decrement on LF-RNS in muscles distant from the injection site strongly supports the diagnosis of iatrogenic botulism.

2.
J Am Coll Emerg Physicians Open ; 3(1): e12654, 2022 Feb.
Article in English | MEDLINE | ID: mdl-35079735

ABSTRACT

OBJECTIVES: To analyze the temporal trends in thrombolysis rates after implementation of a regional emergency network for acute ischemic stroke (AIS). METHODS: We conducted a retrospective study based on a prospective multicenter observational registry. The AIS benefited from reperfusion therapy included in 1 of the 5 primary stroke units or 1 comprehensive stroke center and 37 emergency departments were included using a standardized case report form. The population covers 3 million inhabitants. RESULTS: In total, 32,319 AIS was reported in the regional hospitalization database of which 2215 thrombolyzed AIS patients were included in the registry and enrolled in this study. The annual incidence rate of thrombolysis continuously and significantly increased from 2010 to 2018 (10.2% to 17.3%, P-trend = 0.0013). The follow-up of the onset-to-door and the door-to-needle delays over the study period showed stable rates, as did the all-cause mortality rate at 3-months (13.2%). CONCLUSION: Although access to stroke thrombolysis has increased linearly since 2010, the 3-month functional outcome has not evolved as favorably. Further efforts must focus on reducing hospital delays.

3.
Article in English | MEDLINE | ID: mdl-34751056

ABSTRACT

Mutation in the sorbitol dehydrogenase gene (SORD) has been recently described to cause axonal Charcot-Marie-Tooth disease (CMT), intermediate CMT, and distal hereditary motor neuropathy (dHMN). We herein report the case of a 24-year-old patient diagnosed with juvenile amyotrophic lateral sclerosis (JALS) who carried the homozygous c.757delG mutation in SORD. No other pathogenic variant in frequent JALS-causative genes was found. Our findings expand the phenotype related to SORD mutation, a new and potentially treatable genetic disease.


Subject(s)
Amyotrophic Lateral Sclerosis , Charcot-Marie-Tooth Disease , Amyotrophic Lateral Sclerosis/diagnosis , Amyotrophic Lateral Sclerosis/genetics , Charcot-Marie-Tooth Disease/diagnosis , Charcot-Marie-Tooth Disease/genetics , Humans , L-Iditol 2-Dehydrogenase/genetics , Mutation/genetics , Sorbitol
4.
Cerebrovasc Dis ; 40(1-2): 3-9, 2015.
Article in English | MEDLINE | ID: mdl-25998791

ABSTRACT

BACKGROUND: We evaluated the management, outcome and haemorrhagic risk in a cohort of ischaemic stroke patients with mild symptoms treated with intravenous tissue plasminogen activator (tPA) within the first 4.5 h. METHODS: We analysed data from a prospective stroke thrombolysis registry. A total of 1,043 patients received tPA between 2010 and 2014 in the 5 stroke units of the RESUVAL stroke network (Rhône Valley, France). Among them, 170 patients had a National Institute of Health Stroke Scale (NIHSS) score ≤4 (minor group: MG) before tPA and 873 patients had a NIHSS score >4. RESULTS: A high rate (77%) of excellent outcome (3-month-modified Rankin Scale score ≤1) was observed in the MG. No symptomatic intracerebral haemorrhage occurred and the rate of any haemorrhagic transformation was 5%. Fifty-four percent of the MG patients had visible arterial occlusion before tPA. Patients of the MG were less likely to be transported by Emergency Medical Services and to be directly admitted to the stroke unit or to imaging. Median delays from onset to admission, from admission to imaging and from onset to tPA were longer in the MG. CONCLUSION: Our data provided evidence of safety and suggested potential benefit of thrombolysis in patients with NIHSS score ≤4. A majority of these patients exhibited arterial occlusion before thrombolysis. Most often, patients with mild stroke are not given priority in terms of the mode of transport, direct admission to stroke unit and rapid imaging, resulting in an increased delay from onset to thrombolysis. Health system improvements are needed to provide all suspected stroke victims equal access to imaging and treatment on an emergency basis.


Subject(s)
Fibrinolytic Agents/administration & dosage , Stroke/drug therapy , Thrombolytic Therapy , Tissue Plasminogen Activator/administration & dosage , Aged , Aged, 80 and over , Cerebral Hemorrhage/chemically induced , Diagnostic Imaging/methods , Disability Evaluation , Female , Fibrinolytic Agents/adverse effects , France , Humans , Infusions, Intravenous , Male , Middle Aged , Patient Admission , Registries , Retrospective Studies , Risk Factors , Severity of Illness Index , Stroke/diagnosis , Thrombolytic Therapy/adverse effects , Time Factors , Time-to-Treatment , Tissue Plasminogen Activator/adverse effects , Transportation of Patients , Treatment Outcome
5.
Respir Care ; 58(9): 1424-32, 2013 Sep.
Article in English | MEDLINE | ID: mdl-23322888

ABSTRACT

OBJECTIVE: To assess factors that predict good tolerance of noninvasive ventilation (NIV), in order to improve survival and quality of life in subjects with amyotrophic lateral sclerosis. METHODS: We conducted a prospective study in subjects with amyotrophic lateral sclerosis and requiring NIV. The primary end point was NIV tolerance at 1 month. Subjects, several of whom failed to complete the study, were classified as "tolerant" or "poorly tolerant," according to the number of hours of NIV use (more or less than 4 h per night, respectively). RESULTS: Eighty-one subjects, 73 of whom also attended the 1-month follow-up visit, participated over 34 months. NIV tolerance after the first day of utilization predicted tolerance at 1 month (77.6% and 75.3% of subjects, respectively). Multivariate analysis disclosed 3 factors predicting good NIV tolerance: absence of airway secretions accumulation prior to NIV onset (odds ratio 11.5); normal bulbar function at initiation of NIV (odds ratio 8.5); and older age (weakly significant, odds ratio 1.1). CONCLUSION: Our study reveals 3 factors that are predictive of good NIV tolerance, in particular the absence of airway secretion accumulation, which should prompt NIV initiation before its appearance.


Subject(s)
Amyotrophic Lateral Sclerosis/complications , Noninvasive Ventilation , Respiratory Insufficiency/therapy , Sputum/metabolism , Age Factors , Female , Gastrostomy/adverse effects , Humans , Male , Middle Aged , Multivariate Analysis , Prospective Studies , Respiratory Function Tests , Respiratory Insufficiency/etiology
6.
J Neurol ; 259(1): 39-46, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21656342

ABSTRACT

Triple-A or Allgrove syndrome is a rare multisystem disease classically associated with esophageal achalasia, adrenal insufficiency and alacrima. Here, we describe the poorly understood neurological characteristics often associated with this condition, through the clinical and electrophysiological analysis of eight patients. All patients were genetically confirmed and had a mutation in the ALADIN gene. They all displayed a classical picture of Triple-A syndrome: all suffered from achalasia and alacrima and half of them from adrenal insufficiency. However, all harbored a neurological picture characterized by a recognizable pattern of peripheral neuropathy. Other neurological features included cognitive deficits, pyramidal syndrome, cerebellar dysfunction, dysautonomia, neuro-ophthalmological signs and bulbar and facial symptoms. This neurological picture was prominent in all patients and misled the initial diagnosis in six of them, which had a late onset. We then review the previous neurological reports of this disease, to improve the understanding of this rare condition. Diagnosis of late-onset Triple-A syndrome is difficult when the clinical picture is mainly neurological and when endocrine or gastrointestinal signs are minor. The characteristics of the peripheral neuropathy, among other neurological signs, can be of help.


Subject(s)
Adrenal Insufficiency/pathology , Esophageal Achalasia/pathology , Nervous System Diseases/pathology , Adrenal Insufficiency/diagnosis , Adrenal Insufficiency/etiology , Adrenal Insufficiency/genetics , Adult , Age of Onset , Aged , Brachial Plexus Neuritis/etiology , Electrodiagnosis , Esophageal Achalasia/diagnosis , Esophageal Achalasia/etiology , Esophageal Achalasia/genetics , Female , Gait Disorders, Neurologic/etiology , Humans , Male , Middle Aged , Motor Neurons/physiology , Peripheral Nervous System Diseases/etiology , Retrospective Studies , Thorax/abnormalities , Tongue/pathology , Young Adult
7.
Mov Disord ; 27(1): 84-9, 2012 Jan.
Article in English | MEDLINE | ID: mdl-21994070

ABSTRACT

Depression is frequent in Parkinson's disease, but its pathophysiology remains unclear. Two recent studies have investigated the role of serotonergic system at the presynaptic level. The objective of the present study was to use positron emission tomography and [(18)F]MPPF to investigate the role of postsynaptic serotonergic system dysfunction in the pathophysiology of depression in Parkinson's disease. Four parkinsonian patients with depression and 8 parkinsonian patients without depression were enrolled. Each patient underwent a scan using [(18)F]MPPF, a selective serotonin 1A receptor antagonist. Voxel-by-voxel statistical comparison of [(18)F]MPPF uptake of the 2 groups of parkinsonian patients and with 7 matched normal subjects was made using statistical parametric mapping (P uncorrected < .001). Compared with nondepressed parkinsonian patients, depressed patients exhibited reduced tracer uptake in the left hippocampus, the right insula, the left superior temporal cortex, and the orbitofrontal cortex. Compared with controls, nondepressed parkinsonian patients presented reduced [(18)F]MPPF uptake bilaterally in the inferior frontal cortex as well as in the right ventral striatum and insula. Compared with controls, [(18)F]MPPF uptake was decreased in depressed parkinsonian patients in the left dorsal anterior cingulate and orbitofrontal cortices, in the right hippocampic region, and in the temporal cortex. The present imaging study suggests that abnormalities in serotonin 1A receptor neurotransmission in the limbic system may be involved in the neural mechanisms underlying depression in patients with Parkinson's disease.


Subject(s)
Depression/diagnostic imaging , Depression/etiology , Parkinson Disease/complications , Receptor, Serotonin, 5-HT1A/metabolism , Adult , Aged , Aminopyridines/pharmacokinetics , Brain/diagnostic imaging , Brain/drug effects , Female , Fluorine Radioisotopes , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Parkinson Disease/diagnostic imaging , Piperazines/pharmacokinetics , Positron-Emission Tomography , Serotonin Antagonists/pharmacokinetics
8.
Eur Neurol ; 64(2): 114-6, 2010.
Article in English | MEDLINE | ID: mdl-20639635

ABSTRACT

BACKGROUND: Episodic ataxia type 2 (EA2) is characterized by paroxysmal bouts of ataxia and progressive cerebellar dysfunction. Other manifestations may also be associated, such as migraine attacks with or without aura, absence epilepsy and mental retardation. METHODS: To describe the intrafamilial variability of clinical manifestations of 3 patients harboring a novel CACNA1A point mutation in exon 7 (nucleotide insertion c.1063dupG) typical of EA2 mutation. RESULTS: All 3 patients presented paroxysmal bouts of ataxia, but age of onset, associated symptoms and symptoms at clinical onset were clearly distinct with hemiplegic migraine attacks in the father, absence epilepsy in one child and mental retardation in the other child. CONCLUSION: Typical manifestations of EA2 may be associated and temporally preceded by rare manifestations such as hemiplegic migraine attacks, epilepsy and mental retardation. Moreover, patients sharing a given CACNA1A mutation may present very different phenotypes even within the same family.


Subject(s)
Ataxia/genetics , Calcium Channels/genetics , Family Health , Mutation/genetics , Phenotype , Adult , Exons/genetics , Humans , Male
10.
BMJ Case Rep ; 20102010 Oct 12.
Article in English | MEDLINE | ID: mdl-22789694

ABSTRACT

Churg-Strauss syndrome (CSS) is a systemic vasculitis with frequent respiratory tract involvement. It can also affect the nervous system, notably the optic tract. The present work reports the case of a 65-year-old man diagnosed as having CSS in the context of several acute onset neurological symptoms including muscle weakness and signs of temporal arteritis, including bilateral anterior ischaemic optic neuropathy (ON). Electroretinograms (ERGs) and visual evoked potentials (VEPs) were performed. Flash ERGs were normal whereas VEPs were highly abnormal, showing a dramatic voltage reduction, thus confirming the ON. The vision outcome was poor. Ophthalmological presentations of CSS have rarely been reported, but no previous case of sudden blindness documented by combined ERG and VEP investigations were found in the literature. The present case strongly suggests that the occurrence of visual loss in the context of systemic inflammation with hypereosinophilia should lead to considering the diagnosis of CSS.


Subject(s)
Blindness/diagnosis , Churg-Strauss Syndrome/diagnosis , Diplopia/diagnosis , Giant Cell Arteritis/diagnosis , Muscle Weakness/diagnosis , Optic Neuropathy, Ischemic/diagnosis , Aged , Anti-Inflammatory Agents/therapeutic use , Blindness/drug therapy , Blindness/physiopathology , Churg-Strauss Syndrome/drug therapy , Churg-Strauss Syndrome/physiopathology , Cyclophosphamide/therapeutic use , Diplopia/drug therapy , Diplopia/physiopathology , Drug Therapy, Combination , Electromyography , Electroretinography , Evoked Potentials, Visual/physiology , Fluorescein Angiography , Giant Cell Arteritis/drug therapy , Giant Cell Arteritis/physiopathology , Humans , Immunosuppressive Agents/therapeutic use , Male , Median Neuropathy/diagnosis , Median Neuropathy/physiopathology , Methylprednisolone/therapeutic use , Muscle Weakness/drug therapy , Muscle Weakness/physiopathology , Optic Neuropathy, Ischemic/drug therapy , Optic Neuropathy, Ischemic/physiopathology , Prednisone/therapeutic use , Tomography, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL
...